Blockchain Technology and Internet of Things in Business Automation Markets, 2020-2025: Blockchain Technology and IoT Authentication, Authorization,…

Dublin, Feb. 04, 2021 (GLOBE NEWSWIRE) -- The "Blockchain Technology and Internet of Things in Business Automation: Blockchain Technology and IoT Authentication, Authorization, Accounting, Billing, and Settlement 2020 - 2025" report has been added to ResearchAndMarkets.com's offering.

This research evaluates the technology, leading companies, and solutions in the evolving blockchain ecosystem. The report evaluates current and anticipated use cases for blockchain and assesses the market potential globally, regionally, and segmented by deployment type and industry vertical for the period 2020 to 2025.

The research also evaluates key players, solutions, and use cases. It also assesses the prospect of integrating blockchain with other technologies including IoT and artificial intelligence. The report includes detailed forecasts by use case, application, and industry verticals. This includes blockchain applications and solutions for both financial and non-financial markets.

This research also assesses the market for IoT authentication and authorization by technology, solutions, and industry verticals with forecasts from 2020 to 2025. The report analyzes IoT authentication and authorization market drivers and opportunities. The report also assesses IoT authentication and authorization infrastructure requirements.

Target Audience:

Key Topics Covered:

Blockchain Technology Market by Service Type, Applications, Solutions, Industry Verticals 2020 - 2025

1 Executive Summary

2 Introduction2.1 Evolution of Payment Industry2.2 Payments Value Chain and Blockchain2.3 Blockchain Technology2.4 Early Blockchain Implementations2.5 Blockchain Technology SWOT Analysis

3 Blockchain Ecosystem and Marketplace3.1 Blockchain Types and Stakeholders3.2 Blockchain Applications3.3 Blockchain Application in Industry Verticals3.4 Blockchain in the Internet of Things3.5 Blockchain as a Service (BaaS)3.6 Blockchain Stakeholders in ICT3.7 Blockchain to Improve Cybersecurity3.8 Blockchain Investment Analysis3.9 Important Blockchain Consortia and Associations3.10 Blockchain Solutions in Industry Verticals

4 Blockchain Market Outlook and Forecasts 2020 - 20254.1 Global Market Forecast 2020 - 20254.2 Blockchain Markets by Solution

5 Blockchain Vendors5.1 21, Inc.5.2 Accenture5.3 Abra, Inc.5.4 Alphapoint Corporation5.5 Amazon5.6 Baidu5.7 Bitfury Group5.8 Blockchain Global Limited5.9 BlockCypher, Inc.5.10 Bloq5.11 BTL Group (Blockchain Tech Ltd.)5.12 Chain, Inc.5.13 Circle Internet Financial Limited5.14 Coinbase5.15 Coinfirm Ltd.5.16 ConsenSys Systems (ConsenSys)5.17 Credits5.18 Dell Technologies5.19 Deloitte Touche Tohmatsu5.20 Digital Asset Holdings5.21 Digitalx Ltd. (Digital Cc Ltd.)5.22 DMG Blockchain Solutions5.23 Earthport5.24 Factom Inc.5.25 Fidelity Investments5.26 Global Arena Holding, Inc. (GAHC)5.27 HP5.28 Holo5.29 HyperLedger5.30 IBM Corporation5.31 Intelygenz5.32 IOTA5.33 Libra Services, Inc.5.34 Linux Foundation5.35 Microsoft Corporation5.36 Monax5.37 NASDAQ5.38 Overstock5.39 R35.40 Ripple5.41 ShoCard5.42 Tecent

6 Conclusions and Recommendations

IoT Authentication and Authorization by Technology, Solutions, and Industry Verticals 2020 - 2025

1 Executive Summary

2 Introduction2.1 IoT Data2.2 IoT Devices2.3 IoT Identity Management2.4 IoT Trust Environment

3 IoT Authentication and Authorization Market Drivers3.1 Machine Transactions3.2 Edge Computing3.3 Device Management3.4 Data Management3.5 Service Level Agreements

4 IoT Authentication and Authorization Market Opportunities4.1 Support of IoT Data as a Service4.2 IoT Identity Management and AAA as a Service4.3 IoT Mediation and Orchestration

5 IoT Authentication and Authorization Infrastructure5.1 IoT Database Infrastructure5.2 DB Support of IoT Orchestration and Mediation5.3 DB Support of IoT AAA Services5.4 IoT DB Support of IoT Identity Management5.5 IoT DB Support of IoT Data Management and Analytics5.6 IoT DB Registry and Transaction Services

6 IoT Authentication and Authorization Market Analysis and Forecasts 2020 - 20256.1 Global IoT Authentication and Authorization Market Forecast 2020 - 20256.2 Global AI Market Forecast in IoT Authentication and Authorization 2020 - 20256.3 Global IoT Authentication and Authorization Market in 5G Network 2020 - 20256.4 Global IoT Authentication and Authorization Market in Edge Network 2020 - 20256.5 Regional IoT Authentication and Authorization Market Forecasts 2020 - 20256.5.1 IoT Authentication and Authorization Market by Region

7 Conclusions and Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/p6vo63

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See more here:

Blockchain Technology and Internet of Things in Business Automation Markets, 2020-2025: Blockchain Technology and IoT Authentication, Authorization,...

Insights on the Blockchain in Manufacturing Global Market to 2026 – Asia-Pacific is Expected to Dominate the Market – ResearchAndMarkets.com – Yahoo…

TipRanks

Weve got a full month of 2021 behind us now, and a few trends are coming clearer. The coronavirus crisis may still be with us, but as vaccination programs expand, the end is in sight. With President Trump out of the picture, and the Democrats holding both Houses of Congress and the White House, politics is looking more predictable. And both of those developments bode well for an economic recovery this year. Looking back, at the year that was, we can also see some trends that stayed firm despite the pandemic, the shutdowns, and the supercharged election season. One of the most important is the ongoing rollout of 5G networking technology. These new networks bring with them a fuller realization of the promises inherent in the digital world. Faster connections, lower latency, higher online capacity, clearer signals all will strongly enhance the capabilities of the networked world. And it wont just be mundane things like telecommuting or remote offices that will benefit 5G will allow Internet of Things and autonomous vehicles to further develop their potential. There is even talk of medical applications, of remotely located doctors performing surgery via digitally controlled microsurgical tools. And these are just the possibilities that we can see from now. Who know what the future will really bring? To this end, we pulled up TipRanks database to learn more about three exciting plays in the 5G space. According to the Street, we are likely to see further interesting developments in the next few years as this technology takes over. Skyworks Solutions (SWKS) The first 5G name were looking at, Skyworks, is a semiconductor chip manufacturer that brought in $3.4 billion in total revenues for FY2020. Skyworks, which is a prime supplier of chips for Apples iPhone series, saw a massive 68% year-over-year increase in 1QFY21 revenues the top line reached $1.51 billion, a company record, and also much higher than analysts had forecast. Much of Skyworks fiscal Q1 sales success came after Apple launched the 5G-capable iPhone 12 line. Strong sales in the popular handset device meant that profits trickled down the supply line and Skyworks channels a disproportionate share of its business to Apple. In fact, Apple orders accounted for 70% of Skyworks revenue in the recent quarter. iPhone wasnt the only 5G handset on the receiving end of Skyworks chips, however the company is also an important supplier to Koreas Samsung and Chinas Xiaomi, and has seen demand rise as these companies also launch 5G-capable smartphones. Finally, Skyworks supplies semiconductor chip components to the wireless infrastructure sector, specifically to the small cell transmission units which are important in the propagation network of wireless signals. As the wireless providers switch to 5G transmission, Skyworks has seen orders for its products increase. In his note on Skyworks for Benchmark, 5-star analyst Ruben Roy writes: SWKS significantly beat consensus estimates and provided March quarter guidance that is also well ahead of consensus estimates as 5G related mobile revenue and broad-based segment revenue continued to accelerate In addition to continued strength of design win momentum and customer activity, we are encouraged with SWKS confident tone relative to the overall demand environment and content increase opportunities. In line with his comments, Roy rates SWKS a Buy along with a $215 price target. At current levels, this implies an upside of 20% for the coming year. (To watch Roys track record, click here) Roy is broadly in line with the rest of Wall Street, which has assigned SWKS 13 Buy ratings and 7 Holds over the past three month -- and sees the stock growing about 15% over the next 12 months, to a target price of $205.69.(See SWKS stock analysis on TipRanks) Qorvo, Inc. (QRVO) Qorvos chief products are chipsets used in the construction of radio frequency transmission systems that power wifi and broadband communication networks. The connection of this niche to 5G is clear as network providers upgrade their RF hardware to 5G, they also upgrade the semiconductor chips that control the systems. This chip maker has a solid niche, but it is not resting on its laurels. Qorvo is actively developing a range of new products specifically for 5G systems and deployment. This 5G radio frequency product portfolio includes phase shifters, switches, and integrated modules, and contains both infrastructure and mobile products. Qorvo posted $3.24 billion in total revenues for fiscal 2020. That revenue represents a 4.8% year-over-year increase and the companys sales have been accelerating in fiscal 2021. The most recent quarterly report, for the second fiscal quarter, showed $1.06 billion in revenues, a 31% yoy increase. Rajvindra Gill, 5-star analyst with Needham, is bullish on Qorvos prospects, noting: Qorvo reported strong sales and gross margins as 5G momentum rolls into CY21 on atypical seasonality... The company is planning for 500M 5G handsets to be manufactured in 2021, with an incremental $5-7 of content/unit from 4G to 5G. Management believes that ultra-wideband adoption will be a key growth driver in for smartphones going forward..." To this end, Gill puts a $220 price target on QRVO shares, suggesting room for 31% upside in 2021. Accordingly, he rates the stock a Buy. (To watch Gills track record, click here) What do other analysts have to say? 13 Buys and and 6 Holds add up to a Moderate Buy analyst consensus. Given the $192.28 average price target, shares could climb ~15% from current levels. (See QRVO stock analysis on TipRanks) Telefonakiebolaget LM Ericsson (ERIC) From chipsets, well move on to handsets. Ericsson, the Swedish telecom giant has long been a leader in mobile tech, and is well known for its infrastructure and software that make possible IP networking, broadband, cable TV, and other telecom services. Ericsson is the largest European telecom company, and the largest 2G/3G/4G infrastructure provider outside of China. But that is all in the background. Ericsson is also a leader in the rollout of Europes growing 5G networks. Ericsson is involved in 5G rollout in 17 countries in Europe, the Americas, and Asia, and its product line includes infrastructure base units and handsets, giving the company an interest in all aspects of the new 5G networks. Ericssons revenue performance in 2020 was not notably distressed by the corona crisis. Yes, the top line dipped in Q1, but that was in line with the companys historical pattern of rising revenue from Q1 through Q4. While the companys 1H20 revenues showed small yoy declines, the 2H20 gains were higher. In Q3, the $6.48 billion top line was up 8.7% yoy, and Q4s $8.08 billion revenue was up 17% from the prior year. The companys shares have also performed well during the corona year, and show a 12 month gain of 64%. Raymond James 5-star analyst Simon Leopold bluntly assigns Ericssons recent gains to its participation in 5G rollouts. Japan's awaited 5G roll-out has started. Share gains continue as Ericsson benefits from challenges facing its biggest competitors and more operators embrace 5G it seems obvious that Ericsson should be gaining market share... Competitor Nokia shunned the Chinese 5G projects, citing profitability challenges, yet Ericsson appears to be profiting in the challenging region. Leopold rates this stock an Outperform (i.e. Buy), and his $15 price target implies an upside potential of ~14% for the year ahead. (To watch Leopolds track record, click here) The Raymond James analyst, while bullish on ERIC, is actually less so than the Wall Street consensus. The stock has a Strong Buy consensus rating, based on a unanimous 5 reviews, and the $16.50 average price target indicates 25% growth potential from the share price of $13.19. (See ERIC stock analysis on TipRanks) To find good ideas for 5G stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more:

Insights on the Blockchain in Manufacturing Global Market to 2026 - Asia-Pacific is Expected to Dominate the Market - ResearchAndMarkets.com - Yahoo...

The blockchain-based virtual world that can help usher in the metaverse – VentureBeat

One of the essential features of a working metaverse will be the ability to move your avatar and assets seamlessly and instantaneously from world to world. Blockchain may be the thing that makes that possible. And The Sandbox, a world based on the Etherium cryptocurrency, has an approach to perpetual, player-owned tokens that could point the way forward.

The idea of blockchain in the metaverse is to build a new kind of digital asset, to create based on ownership and governance, said Arthur Madrid, CEO and co-founder of The Sandbox, in a conversation with Dean Takahashi, Lead Writer at GamesBeat. The panel, dubbed Blockchain and the Metaverse, was part of the recent GamesBeat event, Into the Metaverse.

The current manifestation of The Sandbox, a virtual world where players can build, own, and monetize their own voxel gaming experiences on the Ethereum blockchain, has just those kinds of assets. Users gain ownership of their creations as non-fungible tokens (NFTs), which means the number of items and the history of their ownership can be tracked, and items can be verified as one-of-a-kind. The value of each individual NFT is also defined by the community. Under the ownership of Animoca Brands, the teams vision is to offer a deeply immersive metaverse in which virtual worlds and games will be created collaboratively and without centralized authority.

The Sandbox features three main components: the VoxEdit NFT builder for building what they call ASSETs, the marketplace for buying and selling ASSETs, and the game maker tool where interactive games can be constructed and shared. These components are intended to allow players to create voxel worlds and game experiences, and the ability to safely store, trade, and monetize their creations through blockchain, allowing creators to benefit from their creations and evolving how digital assets in games are understood, at a fundamental level.

I think people are truly blown away by the amount of money that players spend in digital assets hundreds, thousands, and probably millions of dollars spent on digital assets, he said. I think making those assets NFTs, building an NFT economy, is going to add a new layer on top of the existing digital economy.

Madrid believes that games and worlds built on this style of gameplay will eventually move from a revenue sharing model, where the game company essentially gets a kickback from player creativity, to one where 100% of the revenue will belong to the players. At that point, the value of the metaverse will come from the service you provide players and in return, word of mouth from players will bring new users into the fold.

Plus, for an avatar-centric metaverse, in which people want to create an identity to travel from one virtual world to the next, making that avatar an NFT could be key, Madrid said, pointing at how you could use ERC-1155 to easily import the assets of a player on your metaverse. Because its decentralized, he explained, you could potentially use an API to call any of the items a player used in their gaming session.

NFT stock and blockchain can also be used to build a governance system attached to a unique mechanism.

That will probably move the very simple gameplay and gameplay mechanics to much more advanced gameplay mechanics that, in my opinion, match up with the concept of the metaverse, he said. When you join a metaverse you understand that it comes with a certain kind of gameplay that makes you be part of it, and based on your engagement, based on what you create, based on the personality and the actions that youre going to achieve inside the metaverse, makes you able to vote for it.

Blockchain technology isnt mature enough to be used in the creation of the metaverse quite yet; in a world where youre looking for 60 frames per second, taking minutes to update is a no-flier. But Madrid points out that you wouldnt currently add blockchain to a game with 250 million players its better to build a blockchain metaverse from scratch.

We are experimenting with this new way to transact with blockchain and theres a lot to be improved, he said. However, crypto communities always compare the blockchain technology to internet in the very beginning. In 1999, nobody could believe that you could use the internet at such a level of speed. As soon as [a technology] is adopted, there is always a solution to make it efficient.

Read the rest here:

The blockchain-based virtual world that can help usher in the metaverse - VentureBeat

Russias regulatory sandbox and the implementation of blockchain tech – Cointelegraph

The main challenge companies face when testing and implementing innovative technologies is the need to amend existing legislation. Developing and testing new products based on distributed ledger technology requires special conditions that are often inconsistent with existing regulations.

The solution to this problem would be the introduction of a special regulatory sandbox regime. It means the creation of an ecosystem within which companies and state-owned enterprises can test their developments without legislative obstacles.

Federal law No. 258, On Experimental Legal Regimes in the Field of Digital Innovation in the Russian Federation, came into effect on Jan. 28. It allows new software to be tested to ensure that it is effective and useful, and then, on the basis of the results, to decide whether to change the current legislation to accommodate the innovation. Creating a sandbox in a certain limited area e.g., within one city will allow a certain number of companies to test their digital innovation products.

In addition to DLT, the list includes artificial intelligence, big data, robotics, quantum technologies and others. In doing so, companies will be able to comply with current legislation, with a number of exemptions necessary for them to fully test the new software. In the long term, sandboxes will be an impetus for the creation of new jobs, the emergence of new organizations, and the increased competitiveness of Russian companies in the international market.

The introduction of an experimental legal regime, or ELR, will be possible in the following areas: financial activity, trade, construction, provision of state and municipal services and implementation of state control (supervision) and municipal control, medicine, transport, agriculture, industry, etc. The term of the sandbox is limited to three years and may be extended for another year by decision of the Russian government. It also accepts applications from organizations proposing the introduction of a special legal regime.

Experts acknowledge that the creation of regulatory sandboxes will require an action plan coordinated with the regulator, and ELR participants will have to meet certain requirements. But the new federal law may result in a real opportunity for business representatives to work with innovations and new developments in the digital sphere under a special legal regime. The authorities, in turn, will assess the results and effectiveness of the experiment, deciding on the extension of the sandbox and the need for changes in legislation.

One of the areas where testing in the sandbox can bring notable positive results is the housing and utilities sector. The use of DLT will reduce paperwork, simplify the payment procedure and make billing more transparent. Users will be able to interact directly with suppliers of resources and will know exactly for which services their money has been spent.

According to data provided by the Russian Ministry of Economic Development, eight projects have already been selected in Russia to be included in the regulatory sandboxes. Among them are the initiatives of Mobile TeleSystems, one of the major Russian mobile operators, which include a smart hotel without staff, the possibility of biometric identification when signing contracts for services without a physical presence (by phone), driverless transport and telemedicine. Or it will be able to use CryptoVeche, a blockchain-based voting system, to hold public hearings remotely in St. Petersburg. Then public hearings of local authorities can be moved online, which in turn will make this process more accessible and transparent for residents. Other projects included the nonprofit Big Data Association, the Tomsk Region Administration and the Russian Foundation for Advanced Research Projects.

ELR is a mechanism for testing, and the keyword here is: experimental. This is why the projects are not large, and the spheres are not the most massive, but they are prospective.

In Russia, the central bank was one of the first to evaluate the prospects of creating sandboxes. In 2020, the first project a blockchain platform for the issuance and circulation of digital rights completed its pilot on the basis of the regulatory sandbox it created. The central bank provides opportunities for piloting innovative products in the financial sector; any interested organization can apply to participate in the sandbox.

Regulatory sandboxes are a tool that has been actively used in other countries for a while now. The first sandbox appeared in 2016 in the United Kingdom. It received more than 140 applications, of which 50 were approved by the regulator, and 41 companies successfully completed testing in 2017. However, statistics showed that the majority of applications were in the field of DLT and were presumably used to reduce the costs of existing financial products rather than to create new ones.

Sandboxes have been launched in other countries, and the United States, Australia, Singapore and Thailand have joined the list. As of November 2020, the number of countries is about 50, but some of them have significant differences in their approach to the creation of sandboxes. For example, the Singapore model is quite similar to the British model but involves stricter oversight by the regulator, the Monetary Authority of Singapore. In Australia, access to the sandbox is granted, among other things, to those companies that do not have a license to carry out a certain type of activity in which they plan to test innovations.

Massive global experience with regulatory sandboxes shows that testing new products under experimental legal regimes helps attract investment, as investors are more willing to invest in companies participating in sandboxes. It also allows the latter to set up internal processes and determine pricing and business models.

In addition to the enactment of federal law No. 258, a number of other bills regulating relationships in the field of digital assets and innovation have appeared in Russian legislation over the past few years. Thus, the federal law On Amendments to Parts One, Two, and Article 1124 of Part Three of the Civil Code of the Russian Federation introduced the concept of digital law and described the nature of transactions conducted through smart contracts and signed using electronic digital signatures. It excluded the concept of digital money and equated digital rights with property rights, which leads to the need for changes in tax legislation.

The federal law On Digital Financial Assets, Digital Currency and Amendments to Certain Legislative Acts of the Russian Federation consolidated the concepts of digital financial assets, or DFA, and digital currency and defined the rules for attracting investments by organizations and individual entrepreneurs by issuing digital rights. The federal law regulates the issuance, accounting and circulation of DFA, making it transparent and clear to all participants.

The views, thoughts and opinions expressed here are the authors alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Maxim Rukinov is head of the Distributed Ledger Technologies Center at St. Petersburg State University. He has a law degree and a Ph.D. in economic sciences. Maxim specializes in investment portfolio management and financial analysis. His expertise is confirmed by the MIT Sloan School of Management. He has also authored scientific publications on economic security and the impact of sanctions on the Russian economy.

Go here to read the rest:

Russias regulatory sandbox and the implementation of blockchain tech - Cointelegraph

Blockchain start-up Retraced raises another EUR1m in funding – just-style.com

The blockchain-based platform helps fashion brands to collect information from their supply chain

The Retraced platform helps brands to collect information from their supply chains on suppliers, working conditions, materials, certifications, and environmental impacts and to share this with their customers. This, in turn, helps them tobetter monitor their impact on their supply chains, become more transparent in their operations, and enables customers to make informed purchasing decisions.

The EUR1m in seed funding comes from European VC firmSamaipata and will be used to fuel its expansion andadd innovative new features.The latest investment round follows a successful pre-seed round from 12 months ago.

Since the pandemic hit the industry last year, Retraced has managed to onboard 40 new brands to the platform in the EU and the US in a move it says underlinesa strong interest in supply chain digitalisation for improved transparency and sustainability management.

"Our clients have clear sustainability targets in mind that they want to achieve. Together with them, we have defined the necessary information that they need to manage their sustainability efforts and to evaluate their progress,"says Philipp Mayer, co-founder and CPO.

"We've benefitted from their input, and continue to improve our efficient tracing and document management tools, supplier sustainability assessments, end-consumer communication widget, and other core functions to help them get the actionable overviews they need to get the most out of their investment in sustainability. We are here to accelerate and guide their sustainability efforts."

The firm says theinvestment deal also signals an important opportunity for fashion during a time where the fallout from the pandemic affects the stability and health of supply chains. The values of transparency, compliance, and social responsibility are becoming more important for helping the industry recover and succeed.

"Covid 19 represents a huge challenge, but at the same time a unique opportunity for fashion to refocus and rebuild," says Lukas Pnder, co-founder and CEO of Retraced. "We are building a platform that will help brands produce better, manage their responsibilities to all of their stakeholders, and stay ready for what's to come."

Jos del Barrio, founding partner at Samaipata, adds:"We truly believe we are entering a new era of enterprise transparency towards the end-consumer, given the growing regulatory pressure on compliance management, and the reputational cost of not facing increasing demands from new consumers. 90% of Generation Z affirms that companies are responsible for dealing with social and environmental issues, and we believe there's an amazing opportunity for a platform play in the space, leveraging on network effects between brands and other stakeholders sharing data and best practices and willing to work together for a fairer supply chain management."

Last summer,US denim brand Boyish Jeans harnessedRetraced's solution tocommunicate the sustainable supply chains behind its products to online consumers.

Original post:

Blockchain start-up Retraced raises another EUR1m in funding - just-style.com

Blockchain Cuties Universe to launch DeFi and NFT tokenomics – Cointelegraph

One of the first-ever blockchain games decided that its time for its economy to benefit from what decentralized finance has to offer.

Blockchain Cuties Universe has been around since the very inception of blockchain gaming. During its two and a half years on the blockchain gaming scene, the game launched on five blockchains and developed a great deal of innovative gameplay mechanics.

Blockchain Cuties Universe is a collectible game about the adventures of adorable pets represented by nonfungible tokens on five different blockchains. The game offers vast possibilities to explore, trade and create. Its a very dynamic environment, with regular in-game events and competitions that bring new content and opportunities.

Blockchain Cuties Universe will become the first DeFi game that leverages the power of five blockchains. The games team believes that the synergy of NFT and DeFi technologies will propel the games economy and engagement to new heights.

To achieve the ambitious goal of creating a sustainable, flourishing tokenomics system, Blockchain Cuties Universe will introduce Blockchain Cuties Universe Governance Token (BCUG).

BCUG is a native, digital, cryptographically secured utility token of the Blockchain Cuties Universe ecosystem.

BCUG is a transferable representation of attributed functions specified in the protocol/code of the Blockchain Cuties Universe products, which is intended to be used solely as the primary utility token within the games ecosystem.

BCUG is a non-refundable functional utility token that will be used as the medium of exchange between participants in the games ecosystem. The goal of introducing BCUG is to provide a convenient and secure mode of payment and settlement between players and other economy participants.

BCUG will be supporting various new game mechanics, such as:

The introduction of BCUG and leveraging the power of DeFi will bring a lot of innovation to the game process.

Blockchain Cuties Universe is famous for its community-driven development. The game has a big friendly community of enthusiasts who have been sharing, voting for and lobbying their ideas for years. Their commitment has shaped a lot of gameplay decisions that are present in the game today.

The introduction and further development of BCUG use cases will allow to gamify and support the process of community-driven development in the game.

BCUG holders will be able to vote for, lobby and suggest new game mechanics, updates and in-game aspects. The power of BCUG will make every player with a stake in the game visible and able to influence its future.

BCUG holders will also receive a variety of in-game perks that will give them an advantage in the game.

BCUG holders will have several additional benefits in the game, such as giving players a chance to increase the power of their in-game characters and tradable items.

Every advantage in Blockchain Cuties Universe is also a market opportunity supported by the games five blockchains. So, holding BCUG might prove to be a great opportunity for active market players.

BCUG might prove interesting, even to those outside the world of Blockchain Cuties Universe.

Many of Blockchain Cuties Universe NFTs are held by collectors who dont participate in the game but enjoy investing in the project.

BCUG might become an even more interesting asset thanks to its liquidity and ease of use. Apart from trading opportunities, BCUG will also offer liquidity farming for its holders.

BCUG token will be distributed via two different paths:

The token distribution event is scheduled for Q1 2021 and will consist of two main phases:

For more information on Blockchain Cuties Universe and BCUG token visit: https://blockchaincuties.finance and https://blockchaincuties.com.

This is a paid press release Cointelegraph does not endorse and is not responsible for or liable for any content, accuracy, quality, advertising, products or other materials on this page. Readers should do their own research before taking any actions related to the company. Cointelegraph is not responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in the press release.

Follow this link:

Blockchain Cuties Universe to launch DeFi and NFT tokenomics - Cointelegraph

The India stack that Bill Gates and Sundar Pichai so love is set to get much bigger thanks to the Indian gov – Business Insider India

According to the draft National Strategy on Blockchain, a government-led blockchain infrastructure can become the hub for private developers to build applications.

Advertisement

Sundar Pichai, the CEO of Alphabet, which owns the internet giant Google, in an interview in 2017 had said that UPI and India Stack conversations get him excited. Pichai, who had then said we will see products being built out of India for a global stage, has since then gone on to commit $10 billion into the countrys technology ecosystem.

One of the architects of India Stack Nandan Nilekani, the co-founder of Infosys, had called it the single most important innovation India needs.

Opening up a blockchain infrastructure for similar innovations may lead to bigger advancements in technology than UPI, which is hailed as Indias most successful digital project. We can create our own massive blockchain ledger, say India Ledger, where all researchers and experts come together. The third is that we need to create our own journey with blockchain. Now, is the time to really work on these thoughts, said Prasanna Lohar, head of digital innovations at DCB Bank and a blockchain expert who has been privy to the discussions around blockchain with the government.

Niti Aayog, India's think tank has been working on IndiaChain, India's own ambitious project to develop a nationwide blockchain network, which has revolutionized Indias position as one of the emerging technology players. A few months ago, a blockchain project named Vajra designed by the National Payments Corporation of India for various payment companies providing secured transactions on their online platforms or mobile applications, shows the government is taking proactive initiative to support blockchain, said Neeraj Khandelwal, co-founder of cryptocurrency and bitcoin startup CoinDCX.

SEE ALSO:India becomes the first Asian country to allow small investors to directly lend to the government

Read more from the original source:

The India stack that Bill Gates and Sundar Pichai so love is set to get much bigger thanks to the Indian gov - Business Insider India

DAEM Technology Launches ixWallet and the First Bitcoin Red Packet in Hong Kong to Promote Blockchain Payment Education – Business Wire

HONG KONG--(BUSINESS WIRE)--DAEM Technology Limited (DAEM Technology), a wholly owned subsidiary of ixFintech Group, announced its new product, the ixWallet. ixWallet is a truly distributed ledger wallet, meaning that all the user savings are on the blockchain. It allows users to send/ receive digital assets, as well as to review the ixCrypto Index. The wallet application is now available on both AppStore (for iOS) and Google Play (for Android).

To facilitate the download and use of the ixWallet, and also to promote education in the area of blockchain, DAEM Technology also launched the first Bitcoin Red Packet campaign in Hong Kong. The campaign is for its research on digital payment evolution, as well as collecting feedback from the customers.

Red Packet, also well known as Lai See, Red Envelope, or Lucky Money, is a monetary gift which is given during holidays such as the Chinese New Year, or special occasions such as weddings in Chinese and other East and Southeast Asian societies.

To create the Bitcoin red packet, customers first need to find our Digital Asset Exchange Machine (DAEM) and insert cash in order to exchange it for bitcoin or ethereum. The whole process is self-explanatory and can be easily followed from the guidance provided on the screen. For those without a digital wallet, a paper wallet containing Bitcoin/ Ethereum will be provided. Customers can then place the paper wallet with the bitcoin into our DAEM Red Packet Envelope together with an ixWallet-downloaded QR code and give it to relatives or friends. Alternatively, they can also download the ixWallet App on Apple and Android store first to store their bitcoin instead of using the paper wallet.

Moreover, after the announcement that the DAEM is landing in Cyberport, Hong Kong, DAEM was awarded the Hong Kong Fintech Impetus Awards 2020 and Start Up of the Year by Metro Radio and KPMG, and the Hong Kong Fintech Awards 2020 by ETNet.

Red Packet is one of the most well-known traditional Chinese elements. The Bitcoin Red Packet is a very cheerful and meaningful campaign for us, giving people the opportunity to experience blockchain payments, stated Irene Wong, the founder and CEO of IX Fintech Group. The awards we won also inspire us to keep moving forward. We welcome everyone to visit our experimental store and bring a Bitcoin Red Packet home.

For more details about the DAEM, ixWallet, and the Bitcoin Red Packet, please refer to our website http://daemtech.com/, or visit our experimental store at No. 2 Catchick Street, Kennedy Town, Hong Kong (Near Bank of China).

About DAEM Technology and ixFintech Group

DAEM Technology Limited (DAEM Technology) is a wholly owned subsidiary of ixFintech Group, striving for the evolution of the digital finance world. Its flagship product is the Digital Asset Exchange Machine (DAEM). The first prototype of the machine was completed in May 2020 and officially landed in Cyberport, Hong Kong in December 2020. The machine was awarded the Hong Kong Fintech Impetus Awards 2020 Basic Technology Blockchain by Metro Radio and KPMG in December 2020, and the Hong Kong Fintech Awards 2020 in Wealth Investment and Management by ETNet in January 2021.

ixFintech announced the establishment of ixFintech Group in August 2020. As a former participant of the Cyberport Hong Kong Incubation Program in 2016, ixFintech graduated by launching the ixOption App in August 2018, which was awarded with the ET Net Fintech Award 2018. It was also awarded with the Top 10 Trading Solution Providers in APAC 2019 by CIO magazine in the USA.

About the DAEM and ixWallet

The Digital Asset Exchange Machine (DAEM) is the first next generation De-Fi ATM installed with post quantum computing security. The machine enables the exchange between cash and digital assets (cryptocurrencies, real asset backed tokens, and security tokens) with 3 levels of security. DAEM Technology aims to build the best next generation digital asset financial framework, working together with its decentralized ixWallet, targeted to facilitate exchange between traditional assets and digital assets. It will also make it easier to transfer payments globally, through the instant conversion of different currencies. The whole system is truly decentralized, meaning the savings of the customers are all on the blockchain but not in the machine. The machine is also prepared with a full set of KYC function for future regulatory adoption. Besides, the machine is equipped with patented technology from a Canadian partner IronCap. Every transaction here is tri-protected by network security, time protected token (example OTP) and cryptography technology which supercomputer cannot hack.

Website: http://daemtech.com/

Read this article:

DAEM Technology Launches ixWallet and the First Bitcoin Red Packet in Hong Kong to Promote Blockchain Payment Education - Business Wire

The top global risks facing the world in 2021 and beyond – Consultancy.uk

Infectious diseases, livelihood crises and extreme weather events are the top clear and present dangers facing the world today. A new World Economic Forum report in collaboration with Marsh McLennan, SK Group and Zurich International explores the worlds risk profile.

The analysis is based on a survey of more than 800 people across the globe, who were asked to pinpoint factors that could become a critical threat now and in the future. The backdrop is Covid-19, and the goal is to take a closer look on how it has rocked the world.

The 2021 report reflects the depth and disparity of the pandemics impact, explores how critical global challenges have been exacerbated and reshaped, and highlights the need to address these risks in a more collaborative way, explained Carolina Flint, Managing Director & Risk Management Leader at Marsh.

For a nuanced overview, the researchers broke the global risk profile down into three distinct timelines. Clear & present dangers refer to threats that could hit home within the next two years. Knock-on effects will ensue in the medium term between three and five years from now. Then there are existential threats fundamental issues that could manifest in the next five to ten years.

The clear & present dangers very much reflect the key events of 2020. For instance, the threat frominfectious disease was font and centre cited by nearly 60% of survey respondents. With job losses abound, livelihood crises were labeled a current threat by 55%, while extreme weather events were the third biggest threat presumably relating to bushfires and floods.

With business IT infrastructure stretched across personal and home networks, cyber security has also made its way up the immediate threat profile. Of note in the top five immediate risks is digital inequality where socio-economic disparities are worsened as expensive technology becomes the key to business and personal survival.

A widening digital gap can worsen societal fractures and undermine prospects for an inclusive recovery, explained Daniel Glaser, President & CEO at Marsh McLennan. Indeed, a bigger socio-economic gap could be a severe threat to social cohesion in the future a top concern for 40% of respondents.

In similar vein, many brows are furrowed by the prospect of youth disillusionment stemming from a lost young generation that has now faced two economic crises and icy job markets as a result. These youth stand to lose out on economic opportunities for one, while also facing mental health challenges. Economic stagnation is also a chief risk, while perennial threats from terrorism and environmental damage persist in the backdrop.

These are near term concerns. In the medium term, the threat profile takes on a more economic and financial avatar. Many are worried about asset bubble bursts, price instability, commodity shocks and debt crises all of which are both products and harbingers of a protracted economic crisis.

Technology is also a medium term worry. Digital adoptionleapfrogged several years in a matter of months during the pandemic, and many are worried that the IT infrastructure is simply not equipped for such a boom in volumes. A breakdown of this infrastructure is a top concern, as is a breakdown of its security.

Outside of these factors, the medium term is rife with concerns about international relations. Inter state conflicts, fractured trade relations and resource geopolitisation all of which were key themes unfolding even before the pandemic are prone to return again amid a weak and internalised global economy.

Geopolitical worries persist through the long term as well. Weapons of mass destruction are the top concern in the next five to ten years, while the collapse of states and multilateralism are also dreaded prospects. Half of the survey respondents also expressed concern around the rapid advancement of technology and its implications over a long term horizon on jobs and security.

Then there are a host of environmental risks, which most expect to manifest over the five to ten year horizon. These include loss of biodiversity, natural resource crises, and the failure of concerted climate action. Some fear that the current trends of health and environmental crises might even spur a backlash against science in the future a pattern that is already emerging in some sections of society.

Climate changeto which no one is immunecontinues to be a catastrophic risk. Although lockdowns worldwide caused global emissions to fall in the first half of 2020, evidence from the 20082009 Financial Crisis warns that emissions could bounce back. A shift towards greener economiescannot be delayed until the shocks of the pandemic subside, noted Glaser.

Indeed, action is the need of the hour to navigate this growing risk landscape, each part of which is real and devastating in its own right. Glaser highlights that collaborative efforts could take the world in the right direction, and mitigate some of these challenges.

With governments still deliberating how to pivot away from emergency to recovery, and with companies anticipating a changed business landscape, there are opportunities to invest in smart, clean and inclusive growth that will improve productivity and delivery of sustainable agendas.

Go here to see the original:

The top global risks facing the world in 2021 and beyond - Consultancy.uk

Richard Bransons SPAC to Merge With Gene-Testing Firm 23andMe – Barron’s

Text size

Billionaire Richard Branson has invested in everything from commercial space travel to record labels. Now he is getting into the human genome business.

His blank-check special-purpose company, VG Acquisition Corp. (ticker: VGAC), is merging with the gene-testing company 23andMe and will list it publicly on the New York Stock Exchange under the ticker ME. Under the deal, which values the company at around $3.5 billion, existing shareholders of the gene-testing firm will own 81% of the business.

Branson and Anne Wojcicki, the CEO of 23andMe, will each invest $25 million in a $250 million private investment in public equity, or PIPE. Other investors include funds managed by Fidelity, Altimeter Capital, Casdin Capital, and Foresite Capital. It is expected to close in the second quarter.

The transaction will bring 23andMe gross proceeds of up to $759 million, according to a statement disclosing the deal. That includes the $250 million PIPE and up to $509 million in a VG Acquistion trust account.

For Branson, it is a foray into the booming health-care services industry. 23andMe sells an at-home testing kit that has become popular with consumers who want to learn about their genetic backgrounds. The information can reveal details about genetic health risks in addition to ancestry.

Test users also have the option to participate in genetic research, which 80% accept. The insights from this research can be used to develop future therapies for cancer, heart, and lung disease, among others, the company said.

We have a huge opportunity to help personalize the entire experience at scale, allowing individuals to be more proactive about their health and wellness, said Wojcicki. Through a genetics-based approach, we fundamentally believe we can transform the continuum of healthcare.

Branson said in the same statement that he was excited to see 23andMe make a positive difference to more people.

Consumer genetic testing fits into the growing segment of personalized medicine and health care. Its also an area of controversy over privacy issues.

In 2018, 23andMe joined forces with GlaxoSmithKline (GSK) in a four-year project to use the genetic data 23andMe gathers to develop new drugs.

VG Acquisition shares jumped more than 14% on Thursday, compared with a 0.9% gain in the S&P 500.

Write to Liz Moyer at Liz.Moyer@barrons.com

See the original post here:

Richard Bransons SPAC to Merge With Gene-Testing Firm 23andMe - Barron's

Model organisms are more than just monkeys and mice – DW (English)

Model organisms or research organisms, as they are also known are living things that scientists, such as biologists, use to study human and other animal or plant life.

A model organism can be anything from single-celled bacteria to viruses and fungi. They can be more complex organisms, such as monkeys, mice, rats, frogs, elephants and a salamandercalled axolotl.

Monkeys and mice are considered incredibly important for the study of human disease and ageing, because they are genetically so similar to humans. And research on primates and rodents has led to some major scientific breakthroughs.

Illustration by Per Sander

The field is not without its opponents, though, and let's not mince our words its downsides.

One of the most basic scientific and ethical questions asks whether it's okay to subject non-human animals to experimental pain in a laboratory when we wouldn't do that with humans.

Think of vaccines and other medicines: Before they get tested on people, they are tested on non-human animals to look for dangerous side-effects.

Even further down the track, in human clinical trials, people can have extreme and adverse reactions to a drug in development. And that's when the drug has been somewhat refined to limit negative outcomes.

Illustration by Simone Hls

But with monkeys and rats, is it okay to just go ahead and test potentially lethal chemicals? Or what of psychological trials, like studying pain stimuli on mice? Is that okay? Does that mean that a monkey's life is worth less than a human life?

There are regulations to ensure the welfare of animals in research and, increasingly, some technical alternatives, such as computing models that use artificial intelligence and machine learning systems.

They can calculate what may happen if you put a medicinal compound in a body. But you can't avoid testing medicines on animals, including humans, in the end. How else would you know whether there are any benefits for human life?

Illustration by Simone Hls

There are less controversial model organisms than monkeys unexpected yet common things such as tomatoes, fruit flies, worms, and other vegetation. The axolotl is especially interesting because it keeps it's tadpole-like juvenile characteristics into adulthood. This includesexternalgills. But it is not a fish, it's a salamander.

One such plant is even celebrating the 200th anniversary of its naming, or to be precise, its renaming, and that's Arabidopsis thaliana.

A Swiss botanist called A.P. de Candolle coined the term Arabidopsis to describe a group of Brassicaceae plants in the mustard family in 1821.

In a paper published in the Journal of Plant Biochemistry and Biotechnology, Rajnish Khana and Ulrich Kutschera explain how a German botanist, Friedrich Laibach, then "established the mustard plant A. thaliana (L.) Heynh as a model organism in plant genetics []."

It has since become integral to stem cell research and is still delivering insights.

Illustration by Barbara Scheid

Khana and Kutschera write that A. thaliana is an ideal model organism for some very basic reasons: it's small and easy to grow, it has a short generation time the average time from the birth of one living thing to the birth of its offspring it produces up to 10,000 seeds per plant, and it's easy to manipulate and mutate.

Model organisms are categorized into various groups. The categories start with viruses, such as Phage lambda and the Tobacco mosaic virus.

Illustration by Christian Kuhn

The Lambda phage, for instance, is what's known as a temperate virus, which infects host bacteria, such as E.coli.

Being temperate, Phage lambda has different ways of infecting a cell, but it has to decide which it wants to use. And it's that decision-making process at such a fundamental level of life that has intrigued scientists. Studying the process allows them to learn about our own biological development.

Some researchers say it's important to continue studying viruses on the brink of global eradication, such as polio.

Even viruses such as Ebola, Zika and influenza can be used as model organisms to teach us about genetic and hereditary processes in RNA, the messengers of DNA the thing that makes living things unique individuals.

The next category is Prokaryotes. A prokaryote is any organism that lacks a distinct nucleus, the thing that controls the activity of a cell.

Illustration by Barbara Scheid

The most common prokaryotes are bacteria, such as E.coli (Escherichia coli), which is used to study molecular genetics. Synechocystis is a bacterium that is commonly used to research photosynthesis.

Next on the list and arguably the largest and best-known group involves eukaryotes. Eukaryotes are cells or organisms that are thought to have evolved about 2 billion years ago.

Compared to prokaryotes, eukaryotes have a clearly defined nucleus.

They include protists. Protists are often but not exclusively microscopic, single-celled organisms.

Illustration by Christian Kuhn

Eukaryotes also include fungi. There's Neurospora crassa, an orange bread mold, for instance, that's been used to study metabolic regulation and the circadian rhythm the latter being a field that won a Nobel Prize only a few years ago.

Baker's yeast is used in genetic research, as are Coprinus cinereus mushrooms. They have been useful in the study of meiosis, or cell-division, which is important for understanding reproduction.

Arabidopsis thaliana, mentioned above, is also a eukaryote. It belongs to a group of so-called higher plants.

Illustration by Peter Steinmetz

Then there are animals, both invertebrate and vertebrate.

Let's start with invertebrate animals. The US National Wildlife Federation describes invertebrates as the "most diverse and numerous group of animals on Earth."

Invertebrates have no spine. They can live on land or in water.

Illustration by Simone Hls

So, they include animals such as the common fruit fly and hydra, an aquatic animal.

Many have been used in molecular biology or biomedical experiments.

And last, but by no means least, we have the vertebrates arguably, the most controversial group of model organisms.

Vertebrates are defined by their having a spine.

Illustration by Olof Pock

Now, if you wanted to be cynical, you may like to suggest that some vertebrates have more of a spine than others. We humans, for instance, could be accused of being spineless for willingly subjecting other animals to pain that we would rather not endure ourselves. But that argument is up for grabs.

The usual suspects among the vertebrate model organisms are the aforementioned monkeys, rats and mice. But they also include dogs, frogs, chickens and cats, and birds used to study communication among songbirds and non-mammalian auditory systems.

Then there's the beautiful zebrafish, a freshwater tropical specimen.

Zebrafish are virtually transparent. That offers scientists with an almost unique view of an animal's internal anatomy.

Illustration by Simone Hls

But if that's not cool enough, Zebrafish are becoming more and more attractive as a model organism because about 70% of their genes are similar to human genes.

They also have similar bodily components or organs. Zebrafish have two eyes, a mouth, a brain, intestine, pancreas, liver, bile ducts, kidney, a heart, ears, nose, cartilage, and teeth just like humans.

Researchers says it's therefore possible to use zebrafish to model and study genetic changes, which in humans would lead to disease.

That's also one reason why some researchers say zebrafish are becoming more popular in the lab than mice.

Illustration by Simone Hls

Mice are not to be discounted, however. German scientists recently reported that they had cured mice of paralysis after the animals had suffered a spinal cord injury.

But the use of animals, especially those so genetically close to humans, with all the scientific benefits for human life, remains contentious for both scientists and observers of research that uses mammalian model organisms.

Germany's Max-Planck Society writes that "monkeys are used in animal research only if a particular phenomenon cannot be studied on any other species of animal, such as mice, fish or fruit flies. [] They are used primarily for the final drug safety tests on new medicines before they are used on humans."

That is one perspective. Elsewhere, scientists are moving from mice to monkeys.

Illustration by Benjamin St

A feature article in Nature has suggested that cynomolgus macaque monkeys (also known as long-tailed or crab-eating macaques) may be the focus of a "new era of animal models for autism and other brain and psychiatric diseases."

Macaques are already among the most commonly used non-human primates in biomedical research.

The RSPCA, an animal welfare charity in the UK, saysprimates are "highly intelligent animals [] that suffer in similar ways to us."

It goes on to say that "the capture of wild primates for use in breeding colonies and for experiments in some countries causes very significant suffering we believe this is completely unacceptable."I

llustrations by Simone Hls, Christian Kuhn, Olof Pock, Per Sander, Barbara Scheid, Peter Steinmetz, Benjamin St

At a depth of 3,700 meters (12,000 feet), dozens of natural chimneys stick up from the seafloor emitting hot fluid at 290 degrees Celsius (554 degrees Fahrenheit). Over thousands of years, towers of lime have piled up. This is the hydrothermal vent field of the Pescadero Basin, about 150 kilometers east of La Paz in Mexico in the Gulf of California. A marvelous place!

US researchers at the Monterey Bay Aquarium Research Institute discovered the deep-sea vent field at Pescadero Basin in 2015. A few months ago, a research team went back on board the Schmidt Ocean Institute ship Falkor to explore this special place. They mapped the seafloor, recorded high-resolution video and brought back rocks and animal samples.

Due to volcanic activity underground, hot water creeps out of the seafloor, containing chemicals such as hydrogen sulfide - a gas that smells like rotten eggs. It is extremely toxic to humans, but some bacteria can metabolize it and gain energy from it. Those bacteria thrive down here at Pescadero Basin and form these thick, fluffy looking bacterial mats.

The vents are buried in the sediment, so the hot liquid reacts with rocks before it escapes. Therefore, the liquid is clear (like you can see in this picture). At another type of vent called a 'black smoker', dark, metal-rich fluid leaves the chimneys instead. Pescadero harbors life quite different from that what was found at other vent fields explored previously.

The vents are densely covered with tubeworms (Oasisia alvinae). These sessile invertebrates live in chitin tubes just a bit wider than their body. Tubeworms like this one were discovered in the 1970s at a vent field near the Galapagos. The researchers were amazed by how many of these animals live at Pescadero. They are literally everywhere.

Oasisia tubeworms dont have a mouth or a digestive system. Instead, the animals take up hydrogen sulfide and oxygen from the water with their orange-red plumes. They feed the nutrients into a bag filled with bacteria. The bacteria then generate energy for them. It works similar to the bacteria in our guts digesting food for us.

In Pescadero Basin, researchers found species they hadnt seen anywhere else before. Like this iridescent blue scale worm, named Peinaleopolynoe orphanae. Across their back, they have thick discs that refract light - just like the wings of a butterfly. The researchers watched the creatures fighting with each other. They have big jaws which they can project during a fight.

This strange creature is called Xenoturbella profunda, but scientists often call it simply the sock worm. This turns out to be quite literal they are just a bag with a mouth underneath. Scientists saw these strange animals gliding very slowly over the seafloor. They seem to feed on clams, as researchers found clam DNA inside their bodies. How they catch and eat their prey? Nobody knows.

Some animals such as tubeworms, scale worms and Xenoturbella live directly on the hydrothermal vents. Others, though, just float by, like fish or octopuses. Or this guy here, a siphonophore. It resembles a jellyfish, but it's not one. Its more closely related to the venomous Portuguese man o' war.

Apart from animals and rocks, there is more to see in the Pescadero Basin. Underwater lakes like this one, for example. They develop when hot fluid gets trapped under rocks or within caves and cannot escape.

An underwater-robot pilot on the ship steers the remotely-operated vehicle from vent to vent. Via a tether, the robot sends back data and high-resolution video footage to the surface. The researchers can thus see in real-time whats going on down there. An awesome experience, for sure.

The underwater robot has an arm with which it can pick up rocks and animals and bring them back to the surface. But most animals lose their colors and shape pretty soon when conserved in alcohol in the researchers lab. This for a example is a sea cucumber from Pescadero Basin, beautifully colored in life not anymore.

Author: Brigitte Osterath

See the original post:

Model organisms are more than just monkeys and mice - DW (English)

Using proteogenomics to improve the treatment of squamous cell carcinoma – Baylor College of Medicine News

Patients with head and neck squamous cell carcinoma (HNSCC), the sixth most common epithelial cancer worldwide, are treated with surgery, chemotherapy and radiotherapy. In addition, targeted agents, including an EGFR monoclonal antibody (mAb) inhibitor and two programmed cell death protein 1 (PD-1) inhibitors, have been approved by the U.S. Food and Drug Administration for HNSCC treatment, but response rates are moderate.

In this study, researchers led by Baylor College of Medicine, Johns Hopkins University and the National Cancer Institutes Clinical Proteomic Tumor Analysis Consortium (CPTAC) investigated what new insight proteogenomic analysis might offer into understanding why certain patients respond to certain treatments while other patients do not. They propose that their findings may help better match patients to an appropriate course of treatment in the future.

The team profiled proteins, phosphosites (a site on a protein associated with phosphorylation) and signaling pathways in 108 human papillomavirus-negative HNSCC tumors in order to understand how genetic aberrations drive tumor behavior and response to therapies.

We found three subtypes of head and neck squamous cell carcinoma, and each subtype may be a good candidate for a different type of therapy EGFR inhibitors, CDK inhibitors or immunotherapy, saidDr. Bing Zhang, lead contact of the study and professor in theLester and Sue Smith Breast Centerand theDepartment of Molecular and Human Geneticsat Baylor. We also identified candidate biomarkers that could be used to match patients to effective therapies or clinical trials.

One important finding involved matching HNSCC patients to EGFR mAb inhibitors. Cetuximab, an EGFR mAb medication, was approved by the FDA in 2006 as the first targeted therapy for HNSCC, however the success rate for this treatment is low. Moreover, EGFR amplification or overexpression cannot predict response to EGFR mAbs. In this study, researchers found that EGFR ligands, instead of EGFR itself, act as the limiting factor for EGFR pathway activation. When ligand is low, the downstream pathway will not be triggered, even if EGFR protein is highly overexpressed.

We proposed that the EGFR ligand should be used as a biomarker, rather than EGFR amplification or overexpression, to help select patients for the EGFR monoclonal antibody treatment, said Zhang, a member of the Dan L Duncan Comprehensive Cancer Center, a Cancer Prevention & Research Institute of Texas (CPRIT) Scholar and aMcNair Scholarat Baylor.

Tumors with high EGFR amplification do not necessarily have high levels of EGFR ligands, which may underlie their lack of response to EGFR mAb therapy. The team confirmed this hypothesis by analyzing previously published data from patient-derived xenograft models and a clinical trial.

Additionally, tracking a key tumor suppressor known as Rb (retinoblastoma), the research team identified a striking finding that suggests that Rb phosphorylation status could potentially be a better indicator of a patients response to CDK4/6 inhibitor therapy. The study showed that the many mutations in the genes regulating CDK4/6 activity were neither necessary nor sufficient for activation of CDK4/6.

The team found that the CDK4 activity was best measured through Rb phosphorylation measurements, thus identifying a potential measure for patient selection in CDK inhibitor clinical trials.

The research team also found important insights into the effectiveness of immunotherapy. PD-1 inhibitors target the interaction between immune checkpoints PD-1 and PD-L1, but success rates of immunotherapy are low, even when PD-L1 expression is used for patient selection. The researchers examined tumors with high expression of PD-L1 and found that when a tumor overexpresses PD-L1, it also upregulates other immune checkpoints, thus allowing the tumor growth despite the use of PD-1 inhibitors.

This observation suggests that PD-1- and PD-L1-activated tumors with hot immune environments may require multiple types of immunotherapy, which target different immune checkpoint proteins, to be effective.Conversely, tumors with cold immune environments are not good targets for immunotherapy.

Immune-cold tumors are tumors that contain few if any infiltrating immune T cells. Examination of how a tumor becomes immune-cold showed that the problem stems from a flaw in its antigen presentation pathway, a first step toward triggering an immune response against tumor antigens. In immune-cold tumors multiple key gene components of the antigen presentation pathway were deleted. As a result, although tumor antigens are being expressed, the immune system is not able to recognize them on the surface of cancer cells and therefore fails to activate the bodys defense system against the tumor. These deletions have the potential to be effective targets for future therapies.

This study extends our biological understanding of HPV-negative HNSCCs and generates therapeutic hypotheses that may serve as the basis for future studies and clinical trials toward molecularly-guided precision medicine treatment of this aggressive cancer type, saidDr. Daniel W. Chan, co-corresponding author of the study, professor of pathology and oncology, and director of theCenter for Biomarker Discovery and Translationat theJohns Hopkins University School of Medicine.

Find all the details of this study and a full list of contributing authors in the journalCancer Cell.

This work was supported by grants U24 CA210954, U24 CA210985, U24 CA210972, U24 CA210979, U24 CA210986, U24 CA214125, U24 CA210967, and U24 CA210993 from the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC), by a Cancer Prevention Institute of Texas (CPRIT) award RR160027, by grant T32 CA203690 from the Translational Breast Cancer Research Training Program, and by funding from the McNair Medical Institute at the Robert and Janice McNair Foundation.

By Molly Chiu

Read the original here:

Using proteogenomics to improve the treatment of squamous cell carcinoma - Baylor College of Medicine News

New Allen Distinguished investigators will tackle unanswered questions about metabolism and the immune system – PRNewswire

SEATTLE, Feb. 3, 2021 /PRNewswire/ --Just like us, immune cells need fuel to do their jobs. Despite the tight links between human health including our immunity and how our bodies process what we eat, the intersection of immunology and metabolism remains a poorly understood area of human biology.

New awards announced today by The Paul G. Allen Frontiers Group, a division of the Allen Institute, aim to improve that understanding by supporting four research projects in the emerging field of immunometabolism. The projects, which are led by 10 new Allen Distinguished Investigators working in teams of two or three lead investigators per award, will explore new avenues of basic biology, health, disease, and technology development, all focused on unanswered questions about how the immune system and metabolism work together.

In recent years, as Frontiers Group staff met with scientific experts to identify future areas of interest, the topic of metabolism and its intersection with the immune system kept coming up, said Frontiers Group Director Kathy Richmond, Ph.D., M.B.A. As they delved into the unknowns, Richmond and her team realized that any significant progress in these areas could improve human health.

"In so many diseases, a tipping point is reached where entire systems in our bodies are thrown off balance. Studying the complex and fascinating interactions between the immune system and energy metabolism will give us a better understanding of what it means to be healthy and how it might be possible to return those systems to balance after damage or disease," Richmond said. "The innovative and pioneering visions of these four teams of Allen Distinguished Investigators span a variety of approaches to tackle this exciting area of biomedical research."

Each award confers $1.5 million in funding over three years for a total of $6 million awarded for immunometabolism research. The Frontiers Group, founded by the late philanthropist Paul G. Allen in 2016, recommends funding from the Paul G. Allen Family Foundation to researchers around the world whose work has the potential to accelerate scientific discoveries or launch entirely new avenues of exploration.The Allen Distinguished Investigator program was launched in 2010 by Allen to back creative, early-stage research projects in biology and medical research that would not otherwise be supported by traditional research funding programs. Including the 10 new investigators announced today, a total of 92 Allen Distinguished Investigators have been appointed.

The four new research projects include research on human disease, basic biology of the mammalian immune system, and technology development that could impact many areas of immunology and metabolism research.

"The whole field of immunometabolism is relatively new, and it's a great time to be studying this area because there are also new technologies that allow for exploration of metabolic processes within cells and tissues," said Dan Littman , M.D., Ph.D., a professor of immunology and microbiology at NYU Langone Health. "It's an exciting and emerging area, and there aren't many other avenues for funding immunometabolism research as of yet."

Meet the new Allen Distinguished Investigators

Will Bailis, Ph.D.Children's Hospital of PhiladelphiaChris Bennett, M.D.University of PennsylvaniaRuaidhr Jackson, Ph.D.Harvard Medical SchoolAll of us are made up of trillions of cells, yet it is unclear how these cells simultaneously behave as individuals and as part of a collective that makes up who we are. Drs. Will Bailis, Chris Bennett and Ruaidhri Jackson are leading a project to better understand the many links between immunity and metabolism at the scale of individual cells, organs and the entire body. These inextricable links how our diet affects our immune system, and how our immune cells in turn change metabolism tie into all aspects of human health and disease, including cancer, diabetes and heart disease. Using laboratory mice, the researchers will study how an animal's food affects energy production inside immune cells by genetically engineering those cells to "ignore" changes in diet. In tandem, they will study how one particular type of immune cell, known as tissue resident macrophages, uses metabolism to govern not only its own cellular function, but the function of tissues and the entire body.

Aida Habtezion, MD, MSc.Stanford University School of MedicineNandita Garud, Ph.D., MS.University of California, Los AngelesCarolina Tropini, Ph.D.University of British ColumbiaInflammatory bowel disease, or IBD, is a class of immune diseases that stem from chronic inflammation in the intestines. Patients with IBD have widely varied symptoms and responses to treatment which can't be fully explained by human genetics. Drs. Aida Habtezion, Nandita Garud and Carolina Tropini are leading a project to explore how patients' immune responses, metabolism, gut microbiomes and environments may contribute to that variability, using a registry of hundreds of IBD patient volunteers. Better understanding the details of variation between patients, and the reasons behind that diversity, could lead to better, more tailored treatments for this class of often crippling illnesses.

Russell Jones, Ph.D.Van Andel InstituteYasmine Belkaid, Ph.D.National Institute for Allergies and Infectious DiseaseLike all cells, our immune cells need energy from the food we eat to do their jobs. Drs. Russell Jones and Yasmine Belkaid have recently found that T cells, an important type of immune cell that surveys the body and detects and eliminates infected cells, use multiple kinds of fuel when they are working their hardest. Now, they are leading a project to better understand T cells' preferred fuel sources, uncovering which types of T-cell metabolism are needed for optimal infection-fighting and which types might lead to immune dysfunction.

Jennifer Prescher, Ph.D.Michelle Digman, Ph.D.University of California, IrvineTo better understand the immune system and how it dovetails with metabolism, researchers need better toolkits to track and manipulate multiple kinds of cells and molecules at once, over time, in a living animal. Drs. Jennifer Prescher and Michelle Digman are leading the development of a new technique to shine "biological flashlights" on many different immune- and metabolism-related molecules at the same time. The technique, which they dub bioluminescent phasor, will ultimately yield a large toolkit of optical tags that can light up multiple processes or proteins in the laboratory mouse's immune system at once. Once complete, the toolkit would be available for any research lab to use, opening new avenues for discoveries about the immune system and its relationship to our diet.

About The Paul G. Allen Frontiers GroupThe Paul G. Allen Frontiers Group, a division of the Allen Institute,is dedicated to exploringthe landscape of bioscience to identify and foster ideas that will change the world. The Frontiers Group recommends funding through award mechanisms to accelerate our understanding of biology, including: Allen Discovery Centers at partner institutions forleadership-driven, compass-guided research; and Allen Distinguished Investigatorsforfrontier explorations with exceptional creativity and potential impact.The Paul G. Allen Frontiers Groupwas foundedin 2016 by the late philanthropist and visionary Paul G. Allen. For more information, visit allenfrontiersgroup.org.

About the Paul G. Allen Family Foundation

For more than four decades the Paul G. Allen Family Foundation has focused on changing the trajectory of some of the world's toughest problems. Founded by philanthropists Jody Allen and the late Paul G. Allen, co-founder of Microsoft, the Foundation initially invested in community needs across the Pacific Northwest with a focus on regional arts, under-served populations, and the environment. Today, the Foundation supports a global portfolio of frontline partners working to preserve ocean health, protect wildlife, combat climate change, and strengthen communities. The Foundation invests in grantees to leverage technology, fill data and science gaps, and drive positive public policy to advance knowledge and enable lasting change.

Media Contact: Rob Piercy, Director, Media Relations206.548.8486 | [emailprotected]

SOURCE The Paul G. Allen Frontiers Group

Read more:

New Allen Distinguished investigators will tackle unanswered questions about metabolism and the immune system - PRNewswire

Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs – PRNewswire

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ --Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. and BioLabs announced today the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups aiming to innovate in the complex field of neurological diseases. The incubator space is located at the Eisai Center for Genetics Guided Dementia Discovery (G2D2) facility and will become part of BioLabs' national biotechnology network.

"We are excited to announce this collaboration with BioLabs," said Nadeem Sarwar, Ph.D. and President of G2D2. "This specialized incubator will be the first of its kind. With BioLabs' focus on building ecosystems that foster rapid innovation combined with G2D2's state-of-the-art technology to support neurological research, we believe the creation of the Eisai Innovation Center BioLabs will fuel new scientific discoveries and insights. With more than 50 million people globally living with dementia1, there has never been a greater need for the discovery of novel approaches to prevention and treatment."

Housed in the G2D2 facility, the Eisai Innovation Center BioLabs aims to host five to seven neurology-focused start-ups and provide the infrastructure and support to help build their biotech companies. The facility was custom-designed for discovery research, including capabilities for in-vitro biology, molecular and cellular biology including BioSafety Level 2 tissue culture, microscopy, chemical and structural biology and screening. Companies hosted at this incubator will have the opportunity to access the BioLabs network, and interact with the Eisai network, including G2D2 and Eisai's investment arm, Eisai Innovation Inc.

"Launching this incubator space in partnership with BioLabs is an important milestone in our relentless pursuit of a cure for neurological diseases, including Alzheimer's disease, and the fulfillment of our human health care mission. In this new specialized model, we want to advance beyond offering only co-working space," said Vanessa Almendro, MBA, Ph.D. and Head of Strategy and External Innovation at G2D2. "By providing scientific support and enabling potential collaborative opportunities, the Eisai Innovation Center BioLabs is pioneering in providing unique, broad and tailored support to the most prominent biotech companies developing transformative therapies, devices and digital solutions for patients suffering from neurological disorders."

The integration with BioLabs, a national, membership-based network of shared lab and office facilities located in key biotech innovation clusters, empowers companies to rapidly launch their operations in a full-equipped, ready-to-use facility, while collaborating with other innovators in the field.

"The custom-designed space at G2D2 is an ideal home for the Eisai Innovation Center BioLabs. The open-lab layout naturally fosters integration between entrepreneurs, all focused on understanding and advancing the field of neurological diseases. Interacting with a community of peers, specifically within a specialized area of research, sparks collaboration and can significantly fast track a start-up's evolution," said Adam Milne, Chief Operating Officer at BioLabs.

A joint selection committee with members of Eisai Inc., Eisai Innovation Inc. and BioLabs representatives will select the companies to be invited. The selection committee will prioritize start-ups focused on neurology, aligned with Eisai's human health care mission and showing strong potential to develop curative therapeutics. To learn more about the incubator, visit our website.

About Eisai Inc. At Eisai Inc., human health care (hhc)is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at http://www.eisai.com/US and follow us on Twitter and LinkedIn.

About Eisai Innovation, Inc.Eisai Innovation, Inc.(EII) is a subsidiary of Eisai Inc. It is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII contributes toour human health care (hhc)mission by prioritizing disease prevention, prediction and treatment through global investments and research collaboration.

About G2D2Eisai Center for Genetics Guided DementiaDiscovery (G2D2) is the first research center focused on immunodementia. As part of Eisai's Neurology Business Group, G2D2 draws upon Eisai's cutting-edge strengths in human genetics, data sciences and precision chemistry to accelerate discovery of breakthrough immunodementia precision therapeutics.

G2D2 is located in the Alewife Research Center in the Alewife area, in the north-west part of Cambridge, which is one of the world's leading biotechnology clusters where private research organizations in addition to academic institutions such as Harvard University, the Massachusetts Institute of Technology and Tufts University are concentrated. Leveraging the benefits of the location, a research space that can be used by external organizations will be set up at G2D2 to enhance collaboration with outstanding researchers and open innovation initiatives to promote immunodementia drug discovery.

About BioLabsBioLabsis a membership-based network of shared lab facilities located in the nation's key biotech innovation clusters, designed exclusively for high-potential, early-stage life science companies. It offers co-working environments that pair premium, fully equipped and supported lab and space with unparalleled access to capital and industry partners. Find out more athttps://www.biolabs.io/

References

Contact:

Eisai Inc. Libby Holman201-753-1945 [emailprotected]

SOURCE Eisai Inc.

http://www.eisai.com

See the original post here:

Eisai and BioLabs Partner to Create the Eisai Innovation Center BioLabs - PRNewswire

Coronavirus variants, vaccines, and where the pandemic is headed – KCPW

Today on In the Hive, a primer on coronavirus variants. Three variants of SARS-Cov-2 have drawn the attention of health officials because they may spread more easily or in some cases may be more deadly than the original. The Centers for Disease Control and Prevention says that the so-called UK Variant has now been detected in more than half of U.S. states including Utah, while the Brazilian variant has been found in Minnesota and the South African variant in Maryland and South Carolina. How do viruses mutate? And what should we be doing to protect ourselves? Dr. Stephen Goldstein, a post-doctoral researcher with the University of Utahs Department of Human Genetics says that all the same rules apply for trying to curb the spread of these versions of the virus. Goldstein also says the vaccines we have appear to build an immune response to these variants, which means there is, still, a light at the end of the pandemic tunnel.

Guest:Dr. Stephen Goldstein, Post-doctoral researcher at the University of Utahs Dept. of Human Genetics

Podcast: Play in new window | Download (32.2MB)

Subscribe: Apple Podcasts | Android |

Related

Read more:

Coronavirus variants, vaccines, and where the pandemic is headed - KCPW

What Experts Think of 23andMe’s COVID-19 Risk Calculator – Healthline

The COVID-19 pandemic has hit some Americans particularly hard.

Older adults, people with certain preexisting health conditions, and members of ethnic and racial minorities are more likely than others to develop serious symptoms of the disease. Theyve faced higher rates of hospitalization and higher rates of death from COVID-19.

To help community members learn how certain risk factors affect the chances of hospitalization in people whove developed COVID-19, the consumer genomics company 23andMe has launched a new interactive tool called the COVID-19 Severity Calculator.

Its interesting because it turns every citizen who looks at it into a bit of an investigator, said Dr. Robert C. Green, MPH, a medical geneticist and physician-scientist at Brigham and Womens Hospital in Boston, Massachusetts.

You can change the age, you can change the body mass index, you can change the ethnicity and see how it influences the risk of hospitalization, he continued.

The tool offers insights into some of the risk factors for hospitalization from COVID-19, but the company notes that its not intended to predict an individual users risk and doesnt take into account genetic risk factors. The tool does not take into account all of the possible risk factors that can affect how the disease develops.

We created the Severity Calculator because people who have visited 23andMes COVID-19 Information Center have consistently been asking for more information about the severity of the virus infection and what factors into why it impacts some people harder than others, Janie F. Shelton, PhD, MPH, a senior scientist at 23andMe, said in a company press release

The COVID-19 Severity Calculator only incorporates nongenetic risk factors for hospitalization from COVID-19.

They make it clear that this is not based on your genetics. But you have to read that. Its not like its in huge bold letters, Green told Healthline.

The tools algorithm is based on data related to age, sex, ancestry, weight, height, exercise frequency, and certain health conditions. Those conditions include fatty liver disease, high blood pressure, and type 2 diabetes.

Green speculates that the company might eventually incorporate genetic data into the tool as more insights on genetic risk factors become available.

I dont know, but I suspect they will be trying to integrate genetic data into it as the weeks go by and they get more [data], he said.

To develop the COVID-19 Severity Calculator, 23andMe drew on findings from its own COVID-19 Research Study.

The company launched this project in April 2020 to identify and study genetic and non-genetic factors that may affect how COVID-19 develops among members of its customer base.

Study participants share saliva samples and complete online questionnaires about their health, including their experiences with COVID-19.

Nearly 10,000 participants report they have tested positive for the virus. Roughly 750 report being hospitalized with severe symptoms of the disease.

The participants in this study do not represent the general population of the United States, reports 23andMe.

The company also notes that neither the study nor the risk calculator incorporate findings from people who have died from COVID-19.

COVID-19 can cause a wide range of symptoms, ranging from mild to life threatening. Multiple research groups around the world are studying how genetic factors may affect those symptoms and how COVID-19 develops.

I am confident that genetics has a role in disease onset and severity, Michael P. Snyder, PhD, chair of the department of genetics and director of the Center for Genomics and Personalized Medicine at Stanford University in California, told Healthline.

Right now, blood type, which is controlled by genetics, has been associated with COVID-19 in several studies. Other genetic loci are [also beginning to be discovered, he said.

Many scientists who are studying these topics have come together to participate in The COVID-19 Host Genetics Initiative. This international research consortium includes Greens research team, as well as 23andMe.

As researchers learn more about the role of genetics in COVID-19, their findings may help them predict who is at greatest risk of developing severe symptoms. This may help experts learn which groups of people are most likely to benefit from certain treatments, said Snyder.

Genetic insights may also help scientists identify new treatment targets and treatment approaches for COVID-19.

Certain markers may offer clues to specific biological vulnerabilities and specific systems in the body that put you at risk, Green said.

If you can pin down more precisely exactly which genes and variants are more responsible, which proteins those genes produce, youve got a head start on thinking about treatments that can moderate those responses, he added.

The rest is here:

What Experts Think of 23andMe's COVID-19 Risk Calculator - Healthline

A patient-powered registry boosts the study of a rare disease | Penn Today – Penn Today

The study of a disease is inherently challenging when patients are few and far between, but doctors at the Perelman School of Medicine have reported a new patient-powered approach that may help to revolutionize the study of rare diseases.

The Penn Medicine researchers, in a paper in Cell Reports Medicine, described a new type of patient registry they recently developed for Castleman disease, a rare disorder involving flu-like symptoms, enlarged lymph nodes, and sometimes life-threatening vital organ dysfunction.

The registry, called ACCELERATE, includes an approach in which Castleman disease patients can enroll directly. The researchers found that this patient-powered approach greatly boosted enrollment and the overall availability of data, compared to the traditional approach in which doctors at a few designated sites can enroll their patients. Another innovative component is that the study team requests and extracts data from the full medical record for each patient who enrolls rather than relying on physicians or patients to enter data, significantly increasing the quantity of data included.

One of the greatest barriers to progress for rare diseases is the lack of high-quality, centralized data, says study senior author David Fajgenbaum, an assistant professor of translational medicine and human genetics at the Perelman School of Medicine who directs the Center for Cytokine Storm Treatment & Laboratory and is a patient with Castleman disease. Using this novel, patient-powered study design to centralize high-quality data through ACCELERATE has been transformative for Castleman disease tracking and clinical trial enrollment and may serve as a model for research on thousands of other rare diseases that have no approved therapies.

Read more at Penn Medicine News.

Read more here:

A patient-powered registry boosts the study of a rare disease | Penn Today - Penn Today

CDC Foundation Aims to Improve Cancer Outcomes Through New Initiative Aimed at Education and Empowerment – PRNewswire

ATLANTA, Feb. 4, 2021 /PRNewswire/ -- This World Cancer Day, the CDC Foundation announced a multi-year initiative to improve cancer outcomes with anew health empowerment program. Led by the Centers for Disease Control and Prevention (CDC) and the CDC Foundation, EmPOWERed Health is focused on empowering and equipping individuals to become their own health champions. The program will also provide tools and resources that will spark better physician-patient communication and improve shared decision-making.

"Research reveals that people who take an active role in their health have a greater feeling of control, are more likely to adopt positive health behaviors and experience better health outcomes," said Lisa Richardson, MD, MPH, and director of CDC's Division of Cancer Prevention and Control. "This is especially important when trying to prevent or manage a serious condition like cancer. Empowerment can result in more people getting cancer screenings, a greater feeling of control during cancer diagnosis and treatment, and a better care plan for cancer survivors."

Health empowerment has never been more important. The COVID-19 pandemic has been particularly tough for individuals going through cancer, with delayed appointments resulting in heightened anxiety. Cancer screening rates have also declined significantlyscreening appointments for breast, cervical, and colon cancers in March 2020 decreased between 86 percent and 94 percent compared with average volumes in the prior three years, according to a study by the medical record company Epic.

"It's critically important we empower individuals to return to care, especially people of color and lower income populations who are disproportionately affected by cancer," said Judy Monroe, MD, president and CEO of the CDC Foundation. "EmPOWERed Health is a unique initiative that will catalyze individuals to become their own health champions."

This program, with financial support from Amgen, will seek input and involvement from individuals from all backgrounds: members of the general public and oncology community, including people with cancer, their care partners, cancer survivors and healthcare providers. Others involved in this effort will include unexpected partners, like technology, entertainment and social media influencers. Kicking EmPOWERed Health off in March, the CDC Foundation will host a virtual hackathon that leverages open innovation to create bold approaches that can educate, raise awareness and trigger positive action.

"At Amgen, we are committed to improving cancer outcomes for allpatients, including those impacted by healthcare inequity. There is good evidence that empowerment and shared-decision making can have a significant impact," said Darryl Sleep, MD chief medical officer at Amgen, "EmPOWERed Health is an opportunity to build and launch innovation that can improve cancer care, and we are excited to grow our long-standing relationship with CDC and the CDC Foundation with this new initiative."

Both healthcare providers and individuals have a role to play in empowerment, and the program will develop tools for both groups. "As both an oncologist and a cancer survivor, I have been a part of both sides of the cancer experience," said Liz O' Riordan, oncologist and breast cancer survivor."Speaking as a clinician, I cannot emphasize enough the importance of treating your patient as an equal partner in healthcare decision making. As a patient, having the information and confidence to express your opinion makes you feel more in control and able to cope with a challenging situation."

For more information and to receive program updates on EmPOWERed Health, visit: http://www.EmpoweredHealth.organd follow us on Instagram.

About the CDC FoundationThe CDC Foundation helps the Centers for Disease Control and Prevention (CDC) save and improve lives by unleashing the power of collaboration between CDC, philanthropies, corporations, organizations and individuals to protect the health, safety and security of America and the world. The CDC Foundation is the go-to nonprofit authorized by Congress to mobilize philanthropic partners and private-sector resources to support CDC's critical health protection mission. Since 1995, the CDC Foundation has raised over$1 billionand launched more than 1,000 programs impacting a variety of health threats from chronic disease conditions including cardiovascular disease and cancer, to infectious diseases like rotavirus and HIV, to emergency responses, including COVID-19 and Ebola. The CDC Foundation managed hundreds of CDC-led programs inthe United Statesandin more than 140 countries last year. For more information, visithttps://www.cdcfoundation.org. Follow the Foundation onTwitter,Facebook,LinkedIn,InstagramandTikTok.

About the Centers for Disease Control and PreventionThe Centers for Disease Control and Prevention (CDC) works 24/7to protect America from health and safety threats. Whether these threats are global or domestic, chronic or acute, curable or preventable, natural disaster or deliberate attack, CDC is the nation's health protection agency.

AboutAmgenAmgenis committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgenfocuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980,Amgenhas grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visitwww.amgen.comand follow us onwww.twitter.com/amgen.

SOURCE CDC Foundation

http://www.cdcfoundation.org

View original post here:

CDC Foundation Aims to Improve Cancer Outcomes Through New Initiative Aimed at Education and Empowerment - PRNewswire

Stockport NHS Trust is at the forefront of Covid-19 research – In Your Area

Wiesia Woodyatt, Research and Innovation Manager for Stockport NHS Foundation Trust

Stockport NHS Foundation Trust has played a key role in two recent medical research projects which have recently published important findings in the ongoing fight against coronavirus.

The trusts research and innovation team based at Stepping Hill Hospital, together with other staff and patients in both the hospital and community, have contributed toward both the GenOMICC study into the relationship between human genes and Covid-19, and the SIREN study aiming at greater understanding of how far individuals who have recovered from Covid-19 are protected from future infections.

Patients seriously ill with coronavirus in the hospitals ICU took part in the GenOMICC study ('Genetics Of Mortality In Critical Care'), a national research project led by a partnership between the University of Edinburgh and Genomics England.

The study tested how patients genetic makeup could influence how they react to the virus, which will help support the vital search for new treatments.

The GenOMICC study has now successfully identified five genes within DNA that were markedly different between ICU patients and volunteers who did not have Covid-19.

This discovery will help to identify those most at risk, and may assist in fast-tracking new therapies into clinical trials to improve recoveries and help patients survive.

The SIREN study, led by Public Health England, aimed to study and understand whether prior infection with SARS-CoV2 (the virus that causes Covid-19) protects against future infection with the same virus.

Over 100 staff members from Stockport NHS Foundation Trust came forward to assist with this.

The newly published SIREN study found those infected are likely to be protected against reinfection for several months, but could still carry the virus in their nose and throat and transmit it to others.

The study shows a person being infected accounts for an 83 per cent rate of protection against being re-infected themselves, but not against passing on to others.

These continuing studies confirm Stockport NHS Foundation Trusts key role in research on fighting coronavirus, as well as a centre for vaccination against the virus.

Wiesia Woodyatt, Research and Innovation Manager for Stockport NHS Foundation Trust said: "The importance of research remains central to the fight against coronavirus.

"We are proud of the role both our patients and staff have contributed to these studies which have taken important steps forward in these areas."

Stepping Hill Hospital is located in Stockport, Greater Manchester.

Shine a spotlight on your neighbourhood by becoming an Area Ambassador.

Click here to learn more!

See original here:

Stockport NHS Trust is at the forefront of Covid-19 research - In Your Area

Bioengineering threats rated as a top biosecurity risk – E&T Magazine

A global team of experts has put together a list of the most urgent biosecurity threats, with bioengineering threats such as DNA-based surveillance among the top-ranked concerns.

The exercise was facilitated by the Centre for Existential Risk (CSER) and the BioRISC project, both based at the University of Cambridge. A group of 41 academics and figures from industry and government submitted 450 questions facing the UK government regarding biological security. These were then debated, voted on and ranked to define the 80 most urgent questions.

The questions were sorted into six categories: bioengineering; communication and behaviour; disease threats; governance and policy; invasive alien species, and securing biological materials and securing against misuse.

The line-up published in PLOS ONE includes questions around whether data from social media platforms should be used to help detect early signs of emerging pathogens; custom DNA synthesis; threats from human-engineered agents, andhow to incorporate biosecurity into science education.

In the year before the pandemic, the UK was ranked second in the world for global health security by the Global Health Security Index a confidence underpinned by its 2018 Biological Security Strategy, said CSERs Dr Luke Kemp, who led the research. Clearly, improvements are needed and not just to be ready for a future Covid-19-like crisis.

We need to plan for a biosecure future that could see anything from brain-altering bioweapons and mass surveillance through DNA databases to low-carbon clothes produced by microorganisms. Many of these seem to lie in the realm of science fiction, but they do not. Such capabilities in bioengineering could prove even more impactful, for better or worse, than the current pandemic.

An international team anonymously scored the 80 issues to produce a priority list of 20 challenges. These weredivided into the most immediate (likely to be faced within the next five years); those on a five-to-10-year timeline, and those a decade or further in the future.

Kemp describes these 20 threats as ranging from the promising to the petrifying.

One of the most immediate threats is surveillance via DNA databases. The Chinese government has already used blood sampling to target the Uighur population, Kemp said, and commercial DNA databases could become the next frontier of surveillance capitalism.

The possibility of using genetic databases for mass surveillance will only grow in coming years, particularly with the rise of new tracking and monitoring methods, powers and apps during the Covid-19 response.

A high-ranked issue for the longer term was malicious uses of neurochemistry. According to the team of experts, advances in bioengineering and neuroscience could lead to beneficial new drugs but also new weapons.

Imagine a world in which law enforcement uses drugs to placate and control crowds, greatly diminishing the promise of non-violent protest movements on climate and social justice, Kemp said. Regulation is critical at both the international and national level. We need to ensure that new insights into the human brain are not weaponised for either the army or police force.

Kemp added: The world, not just the UK, needs a thoughtful, transparent and evidence-based way of identifying emerging issues in biosecurity and bioengineering. Whether it be a new flu pandemic, new bioweapons, or new ways to sequester carbon, forewarned is forearmed.

Sign up to the E&T News e-mail to get great stories like this delivered to your inbox every day.

More:
Bioengineering threats rated as a top biosecurity risk - E&T Magazine